Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade D 29.51 -2.74% -0.83
IOVA closed down 2.74 percent on Friday, July 10, 2020, on 34 percent of normal volume.
Earnings due: Jul 30
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical IOVA trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.74%
Bollinger Band Squeeze Range Contraction -2.74%
Doji - Bearish? Reversal -2.74%
Multiple of Ten Bullish Other -2.74%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Immunotherapy Cancer Treatments Cancer Immunotherapy Antineoplastic Drugs Melanoma Cell Therapy Solid Tumor Adoptive Cell Transfer Metastatic Melanoma Cancer Immunotherapy Products Head And Neck Cancers Breast And Lung Cancer Lymphocytes National Cancer Institute Ocular Melanoma Pembrolizumab Treatment Of Metastatic Melanoma

Is IOVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 41.49
52 Week Low 17.67
Average Volume 2,277,548
200-Day Moving Average 27.26
50-Day Moving Average 32.22
20-Day Moving Average 29.28
10-Day Moving Average 28.93
Average True Range 1.70
ADX 15.69
+DI 17.62
-DI 20.40
Chandelier Exit (Long, 3 ATRs ) 27.69
Chandelier Exit (Short, 3 ATRs ) 31.43
Upper Bollinger Band 31.38
Lower Bollinger Band 27.18
Percent B (%b) 0.55
BandWidth 14.36
MACD Line -0.68
MACD Signal Line -1.02
MACD Histogram 0.3352
Fundamentals Value
Market Cap 2.11 Billion
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -14.19
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.66
Resistance 3 (R3) 31.79 31.21 31.30
Resistance 2 (R2) 31.21 30.66 31.14 31.18
Resistance 1 (R1) 30.36 30.33 30.07 30.23 31.06
Pivot Point 29.78 29.78 29.64 29.71 29.78
Support 1 (S1) 28.93 29.23 28.64 28.80 27.96
Support 2 (S2) 28.35 28.90 28.28 27.84
Support 3 (S3) 27.50 28.35 27.72
Support 4 (S4) 27.37